News and Trends 26 Aug 2022 Aktis Oncology raises millions in funding bringing total to $161M Aktis Oncology announced yesterday (August 25) that it has raised a series A extension financing of $84 million bringing its total capital raised to date to $161 million. The Massachusetts-based company develops targeted alpha radiopharmaceuticals to treat a broad range of solid tumors. Aktis Oncology‘s investors The extension included participation from new health investors Cowen […] August 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Alpha Biopharma announces completion of phase 2/3 clinical study for drug to treat lung cancer Patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases have completed their last visit in a clinical trial studying the drug, Zorifertinib. Drugs developer, Alpha Biopharma, announced the completion today (August 25) of last patient last visit (LPLV) in its international, multicenter EVEREST phase 2/3 study of the next-generation […] August 25, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 3T Biosciences launches with $40M financing 3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Zelluna Immunotherapy announces investment from Takeda Ventures, Inc. Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25) announced an investment from Takeda Ventures, Inc. (TVI), the strategic arm of Takeda. TVI investment joins Zelluna’s latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical […] August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Study findings could lead to new anti-cancer drugs German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system. Many tumor cells mist themselves with a protective ‘perfume’ that disables the immune system. But a drug already approved for other purposes can apparently render this weapon harmless. This is the conclusion of a […] August 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Potential new treatment for angioimmunoblastic T-cell lymphoma? A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop. However, the underlying mechanism by which AITL develops was unknown. Now, a team from the University of Tsukuba in Japan have shown that B […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 24 Aug 2022 To reach Mars, we need biotechnology As we prepare for long-distance space travel and life on Mars, biotechnology will be essential to make spaceships no longer dependent on Earth’s constant supply. “As human beings, we need a constant supply of oxygen. We need constant access to nutritious food, clean water and a safe and clean waste disposal system,” says Italian astronaut […] August 24, 2022 - 11 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Oncolyze seeking investment for AML clinical trials After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […] August 24, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Northwest Biotherapeutics’ pediatric investigation plan approved by MHRA Northwest Biotherapeutics, a biotech company developing DCVax personalized immune therapies for solid tumor cancers, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its pediatric investigation plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […] August 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2022 Emtora to use $16.9M grant to develop treatment for rare genetic disease Emtora Biosciences, a Texas-based clinical-stage biopharmaceutical company, has been awarded a $16.9 million non-dilutive grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The funding will be used to advance the clinical and product development of its lead program, eRapa, an encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis (FAP). […] August 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email